Potential role of a quetiapine metabolite in quetiapine-induced neutropenia and agranulocytosis

Chemical Research in Toxicology

Volumn 25, Issue 5, 2012, Pages 1004-1011

  Li, Xiaohai ^a   Cameron, Michael D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYQUETIAPINE; CLOZAPINE; CYTOCHROME P450 2D6; DRUG METABOLITE; GLUTATHIONE; HYDROGEN PEROXIDE; MYELOPEROXIDASE; QUETIAPINE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANIMAL EXPERIMENT; ARTICLE; BILE; CATALYSIS; CONTROLLED STUDY; DRUG ACTIVATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NEUTROPENIA; NONHUMAN; RADICAL REACTION; RAT;

AGRANULOCYTOSIS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYANIDES; CYTOCHROME P-450 CYP2D6; DIBENZOTHIAZEPINES; FEMALE; GLUTATHIONE; HORSERADISH PEROXIDASE; HUMANS; MALE; NEUTROPENIA; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84861310361     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx2005635     Document Type: Article

References (39)

1. Lindenmayer, J. P., Brown, D., Liu, S., Brecher, M., and Meulien, D. (2008) The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled study Psychopharmacol. Bull. 41, 11-35
2. Small, J. G., Hirsch, S. R., Arvanitis, L. A., Miller, B. G., and Link, C. G. (1997) Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group Arch. Gen. Psychiatry 54, 549-557
3. Bowden, C. L., Grunze, H., Mullen, J., Brecher, M., Paulsson, B., Jones, M., Vagero, M., and Svensson, K. (2005) A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder J. Clin. Psychiatry 66, 111-121
4. Vieta, E., Mullen, J., Brecher, M., Paulsson, B., and Jones, M. (2005) Quetiapine monotherapy for mania associated with bipolar disorder: Combined analysis of two international, double-blind, randomised, placebo-controlled studies Curr. Med. Res. Opin. 21, 923-934
5. Uetrecht, J., Zahid, N., Tehim, A., Fu, J. M., and Rakhit, S. (1997) Structural features associated with reactive metabolite formation in clozapine analogues Chem.-Biol. Interact. 104, 117-129
6. Uetrecht, J. P. (1992) Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis Drug Saf. 7 (Suppl. 1) 51-56
7. Chandrasekaran, P. K. (2008) Agranulocytosis monitoring with Clozapine patients: To follow guidelines or to attempt therapeutic controversies? Singapore Med. J. 49, 96-99
8. Kalgutkar, A. S. and Didiuk, M. T. (2009) Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem. Biodiversity 6, 2115-2137
9. Cowan, C. and Oakley, C. (2007) Leukopenia and neutropenia induced by quetiapine Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31, 292-294
10. Croarkin, P. and Rayner, T. (2001) Acute neutropenia in a patient treated with quetiapine Psychosomatics 42, 368
11. Ruhe, H. G., Becker, H. E., Jessurun, P., Marees, C. H., Heeringa, M., and Vermeulen, H. D. (2001) Agranulocytosis and granulocytopenia associated with quetiapine Acta Psychiatr. Scand. 104, 311-313; discussion 313-314
12. Shankar, B. R. (2007) Quetiapine-induced leucopenia and thrombocytopenia Psychosomatics 48, 530-531
13. Atasoy, N., Erdogan, A., Yalug, I., Ozturk, U., Konuk, N., Atik, L., and Ustundag, Y. (2007) A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31, 1255-1260
14. El Hajj, I., Sharara, A. I., and Rockey, D. C. (2004) Subfulminant liver failure associated with quetiapine Eur. J. Gastroenterol. Hepatol. 16, 1415-1418
15. Naharci, M. I., Karadurmus, N., Demir, O., Bozoglu, E., Ak, M., and Doruk, H. (2011) Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine Am. J. Psychiatry 168, 212-213
16. Shpaner, A., Li, W., Ankoma-Sey, V., and Botero, R. C. (2008) Drug-induced liver injury: Hepatotoxicity of quetiapine revisited Eur. J. Gastroenterol. Hepatol. 20, 1106-1109
17. Bakken, G. V., Rudberg, I., Christensen, H., Molden, E., Refsum, H., and Hermann, M. (2009) Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5 Drug Metab. Dispos. 37, 254-258
18. Grimm, S. W., Richtand, N. M., Winter, H. R., Stams, K. R., and Reele, S. B. (2006) Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics Br. J. Clin. Pharmacol. 61, 58-69
19. Hasselstrom, J. and Linnet, K. (2006) In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions Drug Metab. Drug Interact. 21, 187-211
20. Lu, W. and Uetrecht, J. P. (2008) Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin Drug Metab. Dispos. 36, 1624-1636
21. Moreno, S. N., Stolze, K., Janzen, E. G., and Mason, R. P. (1988) Oxidation of cyanide to the cyanyl radical by peroxidase/H2O2 systems as determined by spin trapping Arch. Biochem. Biophys. 265, 267-271
22. Chen, Y. R., Deterding, L. J., Tomer, K. B., and Mason, R. P. (2000) Nature of the inhibition of horseradish peroxidase and mitochondrial cytochrome c oxidase by cyanyl radical Biochemistry 39, 4415-4422
23. Malencik, D. A., Sprouse, J. F., Swanson, C. A., and Anderson, S. R. (1996) Dityrosine: Preparation, isolation, and analysis Anal. Biochem. 242, 202-213
24. Lai, W. G., Gardner, I., Zahid, N., and Uetrecht, J. P. (2000) Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis Drug Metab. Dispos. 28, 255-263
25. Li, K. Y., Li, X., Cheng, Z. N., Peng, W. X., Zhang, B. K., and Li, H. D. (2004) Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia Acta Pharmacol. Sin. 25, 390-394
26. Gardner, I., Zahid, N., MacCrimmon, D., and Uetrecht, J. P. (1998) A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes Mol. Pharmacol. 53, 991-998
27. Gardner, I., Leeder, J. S., Chin, T., Zahid, N., and Uetrecht, J. P. (1998) A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo Mol. Pharmacol. 53, 999-1008
28. McConville, B. J., Arvanitis, L. A., Thyrum, P. T., Yeh, C., Wilkinson, L. A., Chaney, R. O., Foster, K. D., Sorter, M. T., Friedman, L. M., Brown, K. L., and Heubi, J. E. (2000) Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders J. Clin. Psychiatry 61, 252-260
29. DeVane, C. L. and Nemeroff, C. B. (2001) Clinical pharmacokinetics of quetiapine: an atypical antipsychotic Clin. Pharmacokinet. 40, 509-522
30. Hopenwasser, J., Mozayani, A., Danielson, T. J., Harbin, J., Narula, H. S., Posey, D. H., Shrode, P. W., Wilson, S. K., Li, R., and Sanchez, L. A. (2004) Postmortem distribution of the novel antipsychotic drug quetiapine J. Anal. Toxicol. 28, 264-267
31. Wang, J. S., Zhu, H. J., Markowitz, J. S., Donovan, J. L., and DeVane, C. L. (2006) Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein Psychopharmacology (Berlin, Ger.) 187, 415-423
32. Thyrum, P. T., Wong, Y. W., and Yeh, C. (2000) Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment Prog. Neuro-Psychopharmacol. Biol. Psychiatry 24, 521-533
33. Manjunath, K. and Venkateswarlu, V. (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration J. Controlled Release 107, 215-228
34. Hinchman, C. A. and Ballatori, N. (1994) Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process J. Toxicol. Environ. Health 41, 387-409
35. Hinchman, C. A., Matsumoto, H., Simmons, T. W., and Ballatori, N. (1991) Intrahepatic conversion of a glutathione conjugate to its mercapturic acid. Metabolism of 1-chloro-2,4-dinitrobenzene in isolated perfused rat and guinea pig livers J. Biol. Chem. 266, 22179-22185
36. Kirchheiner, J., Henckel, H. B., Meineke, I., Roots, I., and Brockmoller, J. (2004) Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers J. Clin. Psychopharmacol. 24, 647-652
37. Bertilsson, L., Dahl, M. L., Dalen, P., and Al-Shurbaji, A. (2002) Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs Br. J. Clin. Pharmacol. 53, 111-122
38. De Gregori, M., Allegri, M., De Gregori, S., Garbin, G., Tinelli, C., Regazzi, M., Govoni, S., and Ranzani, G. N. (2010) How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments Curr. Drug Metab. 11, 276-282
39. Rebsamen, M. C., Desmeules, J., Daali, Y., Chiappe, A., Diemand, A., Rey, C., Chabert, J., Dayer, P., Hochstrasser, D., and Rossier, M. F. (2009) The AmpliChip CYP450 test: Cytochrome P450 2D6 genotype assessment and phenotype prediction Pharmacogenomics J. 9, 34-41